IP Library Granted Patent US 9,457,018
Granted Patent B2
US 9,457,018 · App. 13/061,853 · Granted Oct 4, 2016

Method for combating adverse effects arising from antipsychotic treatment

Inventors: Jørgen Scheel-Krüger (Glostrup, DK); Henrik Björk Hansen (København N, DK)
Assignee: Saniona A/S
A61K31/46A61K31/5513
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,457,018
App. No.
13/061,853
Granted
Oct 4, 2016
Kind
B2
Abstract

This invention relates to a method for combating adverse effects arising from antipsychotic treatment. The invention furthermore relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a compound of formula I and an antipsychotic drug.

Claims (18)

1. A method of treatment or alleviation of an adverse effect arising from a previous antipsychotic treatment comprising

administering to a living animal body a combination of

a therapeutically effective amount of [(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octane, or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of an antipsychotic drug, or a pharmaceutically acceptable salt thereof;

wherein the combination is effective in treating or alleviating weight gain associated with the previous antipsychotic treatment.

2. The method of claim 1 , wherein the antipsychotic drug combined with a therapeutically effective amount of [(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octane, or a pharmaceutically acceptable salt thereof is olanzapine or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the living animal body is a human.

4. The method of claim 1 , wherein:

the adverse effect is weight gain;

the previous antipsychotic treatment is treatment with olanzapine or a pharmaceutically acceptable salt thereof; and

the living animal body is a human.

5. The method of claim 1 , wherein the [(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octane, or pharmaceutically acceptable salt thereof; and the antipsychotic drug, or pharmaceutically acceptable salt thereof, are administered simultaneously, sequentially, or separately.

6. The method of claim 1 , wherein the previous antipsychotic treatment is treatment with amisulpride, aripiprazole, asenapine, bifeprunox, clozapine, iloperidone, melperone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, or zotepine, or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the previous antipsychotic treatment is treatment with olanzapine.

8. The method of claim 1 , wherein the previous antipsychotic treatment is treatment with clozapine.

9. The method of claim 6 , wherein the antipsychotic drug combined with a therapeutically effective amount of [(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octane, or a pharmaceutically acceptable salt thereof is amisulpride, aripiprazole, asenapine, bifeprunox, clozapine, iloperidone, melperone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, or zotepine, or a pharmaceutically acceptable salt thereof.

10. The method of claim 7 , wherein the antipsychotic drug combined with a therapeutically effective amount of [(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octane, or a pharmaceutically acceptable salt thereof is olanzapine or a pharmaceutically acceptable salt thereof.

11. The method of claim 8 , wherein the antipsychotic drug combined with a therapeutically effective amount of [(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octane, or a pharmaceutically acceptable salt thereof is clozapine or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Oct 21, 2020
From: SANIONA A/S
To: SANIONA A/S
Reel/Frame 054396/0996 →
CHANGE OF NAME Recorded Jan 22, 2016
From: SANIONA APS
To: SANIONA A/S
Reel/Frame 037578/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2015
From: NEUROSEARCH A/S
To: SANIONA APS
Reel/Frame 034650/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2011
From: SCHEEL-KRUGER, JORGEN; HANSEN, HENRIK BJORK
To: NEUROSEARCH A/S
Reel/Frame 026350/0592 →
Priority Claims (1)
DK 2008 01225 · Sep 4, 2008 · national
Continuity (2)
Provisional Application 61094426 · Sep 5, 2008
Related Publication 20120202796A1 · Aug 9, 2012